Loading...

JSPR JASPER THERAPEUTICS INC US FDA Inspections 8-K Filing

JSPR

JSPR

JASPER THERAPEUTICS INC

(JSPR)

2025 8-K

Financial Results Report

Positive Clinical Update

Management Change

Positive Clinical Update

Financial Results Update

Equity Offering Details

Financial Update

Management Changes

Other Special Situation

Product Expansion

Financial Statements

Stock Sale Agreement

Financial Results

Positive Study Results

Financial Results

Positive Study Results

Management Changes

Annual Meeting and Employme...

Financial Results Announcement

Underwriting Agreement

Reverse Stock Split

Special Meeting of Stockhol...

Earnings Reports

Appointment and Resignation

Delisting Notice

Regulation FD Disclosure

FDA Clearance for Clinical ...

Appointment of CFO

Regulation FD Disclosure

Financial Results

Appointment of Director

Amendment and Restatement o...

Corporate Presentation

Financial Results

Management Changes

Financial Results and Busin...

Appointment of Vishal Kapoo...

Public Offering

Underwriting Agreement for ...

Regulation FD Disclosure

Compliance Regained

Positive Data Announcement

Portfolio Prioritization

External Links:

On December 2, 2025, Jasper Therapeutics reported encouraging preliminary data from its ETESIAN Phase 1b study on briquilimab for allergic asthma and completed an internal investigation regarding previous clinical results from the BEACON study.

AI Assistant

JASPER THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.